B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. The annualized relapse rate was lower with ocrelizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback